GLPG1690 is primarily investigated for its therapeutic potential in treating idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease characterized by scarring of lung tissue. It functions as a selective inhibitor of autotaxin, an enzyme involved in the production of lysophosphatidic acid (LPA), a signaling molecule that contributes to fibrosis, inflammation, and cell proliferation. By reducing LPA levels, GLPG1690 aims to slow down or prevent the progression of fibrosis in the lungs. Clinical trials have evaluated its efficacy and safety in patients with IPF, showing potential in improving lung function and reducing disease advancement. Due to its targeted mechanism, GLPG1690 represents a promising approach in managing fibrotic diseases beyond IPF, including other interstitial lung diseases and conditions involving pathological fibrosis. Its oral bioavailability also supports convenient long-term treatment regimens for chronic conditions.